Journey Medical (DERM) Income from Continuing Operations (2020 - 2026)
Journey Medical (DERM) posted Income from Continuing Operations of 2230000.0 for Q1 2026, down 81.45% on a QoQ basis from 1229000.0 in Q4 2025, and up 45.25% year-over-year from 1535292.43 in Q1 2025.
Journey Medical (DERM) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Journey Medical's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 2230000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 45.25% year-over-year to 2230000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9570000.0 (down 16.11% YoY) and the FY2025 annual result came in at 11413000.0, up 22.21% from the prior year.
- Income from Continuing Operations was 2230000.0 for Q1 2026 at Journey Medical, down from 1229000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 16789000.0 in Q3 2023 and bottomed at 10642000.0 in Q4 2022.
- A 5-year average of 3631470.59 and a median of 3361000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 266.56% in 2023, while the deepest fall reached 635.56% in 2023.
- Journey Medical's Income from Continuing Operations stood at 10642000.0 in 2022, then soared by 79.86% to 2143000.0 in 2023, then soared by 173.82% to 1582000.0 in 2024, then plunged by 177.69% to 1229000.0 in 2025, then plunged by 81.45% to 2230000.0 in 2026.
- Business Quant data shows DERM's Income from Continuing Operations at 2230000.0 in Q1 2026, 1229000.0 in Q4 2025, and 2315000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Journey Medical | 169.02 Mn | 141.80 Mn | 9.70 Mn | -2.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.23 Mn |
| Dec 31, 2025 | -1.23 Mn |
| Sep 30, 2025 | -2.32 Mn |
| Jun 30, 2025 | -3.80 Mn |
| Mar 31, 2025 | -4.07 Mn |
| Dec 31, 2024 | 1.58 Mn |
| Sep 30, 2024 | -2.39 Mn |
| Jun 30, 2024 | -3.36 Mn |
| Mar 31, 2024 | -10.44 Mn |
| Dec 31, 2023 | -2.14 Mn |
| Sep 30, 2023 | 16.79 Mn |
| Jun 30, 2023 | -8.36 Mn |
| Mar 31, 2023 | -10.14 Mn |
| Dec 31, 2022 | -10.64 Mn |
| Sep 30, 2022 | -10.08 Mn |
| Jun 30, 2022 | -7.53 Mn |
| Mar 31, 2022 | -1.38 Mn |
| Dec 31, 2021 | -21.75 Mn |
| Sep 30, 2021 | -10.65 Mn |
| Jun 30, 2021 | -11.87 Mn |